Release--With the upcoming release of Wingspan eTMF 2.0, Wingspan Technology is holding an exclusive preview webinar - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Release--With the upcoming release of Wingspan eTMF 2.0, Wingspan Technology is holding an exclusive preview webinar

Source: Company News Release

With the upcoming release of Wingspan eTMF 2.0, Wingspan Technology is holding an exclusive preview webinar

January 13, 2014; BLUE BELL, PA— Wingspan Technology, Inc. plans to release its Wingspan eTMF overhaul, eTMF 2.0 in Q1 2014. On January 22, 2014, Wingspan will debut its revolutionary eTMF product for the first time for public demonstration.

While many document management system interfaces have remained largely unchanged since the 1990s, Wingspan eTMF 2.0 has been re-designed to provide:

· A user experience modeled on commercial web sites such as Amazon and eBay – dramatically reducing user training time and frustration

· Unprecedented insight into the status and health of ongoing trials

· Simple processes for uploading and checking documents that greatly decrease both the time needed for these processes and the possibility of error

Behind the scenes, Wingspan eTMF 2.0 uses the robust and scalable infrastructure and processes that have a proven track record of supporting users in more than 60 countries worldwide in processing up to 10,000 documents per day. Registration for this demo is currently open; you can register online here.

About Wingspan Technology, Inc.

Wingspan Technology, Inc. is the leading provider of life sciences and eClinical software solutions, including Wingspan eTMF and DocWay, the SharePoint/Documentum integration product suite. Wingspan's talented and knowledgeable engineering and project management teams offer in-depth industry knowledge and experience to companies in life sciences, pharmaceutical, financial services, and other fields.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here